PITTSBURGH--(BUSINESS WIRE)--Cellumen, Inc., the Cellular Systems Biology Company (CSB™), announced today that it has spun-out its personalized medicine unit, which will be called Cernostics Pathology, Inc. The objective of this new company is to become the leading provider of digital imaging pathology and tissue-based diagnostics products and services applied to personalized medicine. Cernostics Pathology will build upon Cellumen’s current collaborations, including the partnership with the Mayo Clinic and Foundation, in developing an advanced breast cancer diagnostic and theranostic test.
